MedPath

gamma-Hydroxybutyric acid

Generic Name
gamma-Hydroxybutyric acid
Brand Names
Xywav
Drug Type
Small Molecule
Chemical Formula
C4H8O3
CAS Number
591-81-1
Unique Ingredient Identifier
30IW36W5B2
Background

Gamma hydroxybutyric acid, commonly abbreviated GHB, is a therapeutic drug which is illegal in multiple countries. It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985). Today Xyrem is a Schedule III drug; however GHB remains a Schedule I drug and the illicit use of Xyrem falls under penalties of Schedule I. GHB is a naturally occurring substance found in the central nervous system, wine, beef, small citrus fruits and almost all other living creatures in small amounts. It is used illegally under the street names Juice, Liquid Ecstasy or simply G, either as an intoxicant, or as a date rape drug. Xyrem is a central nervous system depressant that reduces excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Indication

Used as a general anesthetic, to treat conditions such as insomnia, clinical depression, narcolepsy, and alcoholism, and to improve athletic performance.

Associated Conditions
-
Associated Therapies
-
news-medical.net
·

Study reveals significant increase in recreational ketamine use

Recreational ketamine use among adults surged from 2015 to 2022, with notable increases among those aged 26-34 and college-educated individuals. While initially linked with depression, recent trends show higher use among those without depression. The study underscores the importance of monitoring recreational use and educating on polydrug risks.
today.ucsd.edu
·

Ketamine Use on the Rise in U.S. Adults; New Trends Emerge

Recreational ketamine use among adults surged from 2015 to 2022, with notable increases among those aged 26-34 and with college degrees. While linked to depression initially, recent use rose mainly among non-depressed individuals. Researchers stress monitoring and education to mitigate risks, especially in polydrug use contexts.

Ketamine use on the rise in U.S. adults; new trends emerge

A study reveals a significant rise in recreational ketamine use among adults since 2015, with notable shifts in its association with depression and sociodemographic factors. The research highlights the importance of monitoring recreational use trends to balance clinical benefits against risks, especially among younger adults and those with higher education.
newswise.com
·

Research Alert: Ketamine Use on the Rise in US Adults

Recreational ketamine use among adults surged from 2015 to 2022, with notable increases among those without depression, aged 26-34, and with college degrees. The study highlights the need for monitoring recreational use trends and prevention efforts, especially in educational settings and against polydrug use.

France gets new helpline amid trauma of mass rape trial

A French helpline, CRAFS, addresses drug-facilitated sexual assault, sparked by a high-profile rape trial. It provides symptom guidance and support for victims and healthcare providers, highlighting the need for awareness and training. The service encourages reporting and offers free drug detection kits, aiming to combat this 'new scourge'.
biopharmadive.com
·

Jazz to search for new chief as CEO plans retirement

Jazz Pharmaceuticals announced CEO Bruce Cozadd's retirement plan; he will stay on until a successor is found within a year. Cozadd co-founded Jazz in 2003 and led it through significant growth, including the $7 billion acquisition of GW Pharmaceuticals. The company remains on track to meet its 2024 revenue guidance of $4 billion to $4.1 billion, with a focus on Xywav and Epidiolex. A special committee of independent directors will lead the search for Cozadd's replacement, considering both internal and external candidates.
investing.com
·

Jazz Pharmaceuticals retains stock target, Overweight rating on FDA approval

Jazz Pharmaceuticals received FDA approval for Ziihera, a HER2-targeted therapy for HER2+ biliary tract carcinoma, with a list price of $35,500 per cycle. Piper Sandler reaffirmed its Overweight rating and $163 price target, highlighting growth in the oncology segment. Jazz's strong financial health supports portfolio expansion, with anticipation for 2025 data on Ziihera in first-line HER2+ gastroesophageal adenocarcinoma.
tipranks.com
·

Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio

Jazz Pharmaceuticals (JAZZ) posted Q3 top-and-bottom-line beats, projecting 2024 earnings above expectations, driven by sales growth from Xywav and Epidiolex. The company received accelerated approval for Ziihera, a treatment for HER2-positive biliary tract cancer, and anticipates phase 3 PFS results on Zanidatamab. JAZZ trades at a discount to peers, making it attractive for value investors.
mondaq.com
·

While The Orphan Battles Wage, Jazz Takes A Loss

The District Court upheld FDA's decision that Avadel's Lumryz is clinically superior to Jazz's Xywav, granting Lumryz its own orphan drug exclusivity. Jazz argued FDA's decision violated the Administrative Procedure Act, but the Court found FDA's determination was within its statutory authority and not arbitrary or capricious.
© Copyright 2025. All Rights Reserved by MedPath